Apr 15, 2025 8:30am EDT Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
Mar 27, 2025 8:00am EDT BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
Mar 17, 2025 4:16pm EDT Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
Mar 04, 2025 8:03am EST Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
Feb 25, 2025 7:58am EST Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
Jan 23, 2025 4:15pm EST Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Jan 22, 2025 8:00am EST Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Jan 21, 2025 8:00am EST Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
